Defining the Molecular and Radiologic Phenotype of Progressive Rheumatoid Arthritis-Associated Interstitial Lung Disease (MOUNTAIN)

What this Trial Is About

This research aims to identify patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD) who are at the highest risk for disease progression. The study will evaluate how new quantitative imaging methods and specific blood markers relate to the worsening of RA-ILD. Researchers plan to understand disease progression by collecting and analyzing clinical, radiologic, and biologic information from participants. Participants will undergo various procedures throughout the study, including blood collection for genetic and non-genetic testing, cheek swabs, and assessments related to rheumatology and lung function. Standard clinical tests such as high-resolution computed tomography (HRCT) scans of the lungs, pulmonary function tests, and a 6-minute walk test will be collected if performed as part of clinical care. These procedures will occur at the start of the study (baseline), every four months during clinic visits, and at one and two-year follow-ups. During the study, participants will complete questionnaires and undergo multiple assessments including blood samples and lung function tests. Researchers will use these data to evaluate disease progression over a period of 5 years, focusing on the role of advanced imaging techniques. The study includes regular monitoring and follow-up visits to track changes in lung health and overall condition.

Defining the Molecular and Radiologic Phenotype of Progressive RA Interstitial Lung Disease